A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma

Lenalidomide: an update on evidence from clinical trials

(2010) Meletios-Athanassios Dimopoulos et al.   BLOOD REVIEWS

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies

(2010) Sarah M. Temkin et al.   GYNECOLOGIC ONCOLOGY

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

(2009) F. Gay et al.   BLOOD

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

(2009) G. Aue et al.   HAEMATOLOGICA

Antiangiogenesis in haematological malignancies

(2008) William W. Li et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

(2008) Sharon L. Sanborn et al.   INVESTIGATIONAL NEW DRUGS

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

(2007) Levi S. Downs et al.   CANCER